Verona Pharma ( (VRNA) ) has released its Q4 earnings. Here is a breakdown of the information Verona Pharma presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Verona Pharma, a biopharmaceutical company, focuses on developing and commercializing innovative therapies for chronic respiratory diseases, with its first product, Ohtuvayre, targeting the maintenance treatment of COPD.